Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the progress and challenges in delivering CRISPR/Cas9 systems for in vivo genome editing, highlighting current methods and opportunities for future therapeutic applications.

This review explores the use of skin penetration enhancers like Transcutol® in various formulation systems, discussing their mechanisms and effectiveness in improving transdermal drug delivery without breaching the skin.

This review discusses the design and advances of lipid–polymer hybrid nanoparticles as promising delivery systems for genome editing strategies, highlighting their potential in biomedical applications.

This abstract lists numerous dermatological side effects and reactions associated with various medications but reports no new research findings.

This study found that Litfulo improved hair regrowth in patients aged 12 and older with severe alopecia areata but did not meaningfully improve anxiety or depression symptoms compared to placebo.

Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.

This study explores the use of low-dose naltrexone as a novel treatment for lichen planopilaris, but specific results or outcomes are not detailed in the abstract.

This case report describes a 48-year-old male with severe, itchy hypertrophic lichen planus who showed a 90% improvement in lesions following 4 months of treatment with oral acitretin, with no recurrence 6 months posttreatment.

This review discusses various psychiatric treatments including antipsychotics, insomnia medication, and mood stabilizers, but reports no new clinical results; the authors comment on existing findings and approvals.

This synthesis report details the successful development of a C-14 labeled isotopomer of LY300502, a 5α-reductase inhibitor, through a multi-step radiochemical process.

This paper reports a single case of lichenoid cutaneous sarcoidosis that was unresponsive to standard treatments but showed marked improvement with the administration of oral tranilast.

In this study, researchers analyzed lurasidone's risk profile for treating schizophrenia and bipolar depression, identifying unlisted adverse reactions like hypersexuality, restless leg syndrome, thrombocytopenia, and telogen effluvium, which show probable or possible correlations with the drug.

This study found that treatment with oral tofacitinib, alone or with other therapies, was associated with clinical improvement in most patients with recalcitrant lichen planopilaris.

This study examined monoclonal antibodies LT-1, LT-2, and LT-7, finding they can effectively detect certain antigens on T and B cells involved in various lymphoproliferative diseases, aiding in the diagnosis of both acute and chronic lymphoid neoplasias.

This study suggests that combining bendamustine with tucidinostat may improve survival in patients with relapsed or refractory adult T-cell leukemia/lymphoma, highlighting its potential for clinical investigation.

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.

This case series reported that low-dose naltrexone may benefit patients with lichen planopilaris by reducing scalp symptoms and slowing disease progression, with no adverse effects observed in the patients.

This study found that LY320236 is a competitive inhibitor of type I and a non-competitive inhibitor of type II steroid 5alpha-reductase, indicating its potential as a dual inhibitor with differing modes of activity.

This study suggests that the combination of bendamustine and rituximab is at least as effective and possibly offers a better therapeutic index than other standard regimens as first-line treatment for certain lymphoma patients.

This case report describes a 23-year-old male who developed leukopenia, thrombocytopenia, and rash associated with lamotrigine treatment, emphasizing the importance for clinicians to monitor for serious side effects, especially early in treatment.

This report describes a rare case of painless thyroiditis induced by prolonged off-label use of Lugol’s solution in a 59-year-old woman.

Low-dose naltrexone helps improve symptoms and stabilize frontal fibrosing alopecia and lichen planopilaris.

This study found that 86% of patients with follicular non-Hodgkin's lymphoma were alive and nearly two-thirds remained in complete remission eight years after initial treatment with the radioimmunotherapy drug Bexxar.

This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.

This article describes the development milestones and recent approvals of ritlecitinib for treating severe alopecia areata, with approvals in the USA and Japan and ongoing regulatory reviews in other regions.

In this animal study, the researchers found that administering anionic lipid nanoemulsions called squarticles increased survival rates and mitigated the adverse effects of amitriptyline overdose in rats.

This case study observed a massive lithium overdose in a 38-year-old woman with bipolar disorder, who survived despite extremely high lithium concentrations through continuous venovenous hemodiafiltration.

This animal study found that intravenous administration of anionic squarticles, a lipid nanoemulsion, increased survival rates in rats with amitriptyline overdose by mitigating adverse effects and restoring normal blood pressure, highlighting its potential as a detoxifying antidote.